Advertisement

Topics

CCP reports positive Phase ll data of CCP-020 to treat EBS

19:00 EST 15 Jan 2018 | Net Resources International

Castle Creek Pharmaceuticals (CCP) has reported positive data from a Phase ll trial of diacerein 1% ointment (CCP-020) for the...
Read More...

The post CCP reports positive Phase ll data of CCP-020 to treat EBS appeared first on Drug Development Technology.

Original Article: CCP reports positive Phase ll data of CCP-020 to treat EBS

NEXT ARTICLE

More From BioPortfolio on "CCP reports positive Phase ll data of CCP-020 to treat EBS"

Advertisement
Quick Search
Advertisement
Advertisement